MyOr

Company Overview

Snapshot

Founded in April 2018 by Dr. Ariel Katz and Michael Brandwein, MyOr operates with 11–50 employees. The company has raised $5.5M across two funding rounds from five investors. In February 2026, MyOr announced partnerships with insurance companies, enabling over 90% of parents to receive reimbursement for its services.

Business overview

MyOr develops noninvasive monitoring technologies that leverage data-driven artificial intelligence to predict and prevent chronic conditions in children. The company's core offering is an AI-driven platform designed to predict and mitigate the risk of food allergies, eczema, and related conditions. MyOr serves parents, healthcare providers, and insurance companies, promoting evidence-based practices and nutrition strategies to improve health outcomes and eliminate preventable conditions. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare, Patient Engagement, and Medical Decision Support.

Strategic signal

In February 2026, MyOr announced significant partnerships with insurance companies, which now allow over 90% of parents to receive reimbursement for its services. This development is a strong validation of MyOr's business model and the clinical utility of its AI-driven diagnostic and preventive solutions. For investors, this signals a critical step towards broader market adoption and revenue growth, demonstrating the company's ability to integrate into established healthcare payment systems and expand its reach within the pediatric healthcare market.

Company Intelligence Q&A

What was a key strategic development for MyOr in February 2026?

In February 2026, MyOr announced partnerships with insurance companies, which enable over 90% of parents to receive reimbursement for its services. This move significantly expands access to MyOr's preventive healthcare solutions.

What recognition did MyOr receive in October 2023?

In October 2023, MyOr Diagnostics was awarded the prestigious BNEW Prize for Best New Health Startup at the Barcelona New Economy Week (BNEW) event, recognizing its innovative approach to pediatric healthcare.

What was MyOr's activity regarding its network of nutrition experts in October 2023?

In October 2023, MyOr Diagnostics expanded its network of nutritionists across 20 states in Mexico. This network utilizes MyOr's MyorCare platform to educate parents and help safeguard infants against food allergies and atopic dermatitis.

What was MyOr's involvement in addressing the US baby formula shortage in June 2022?

In June 2022, MyOr, through its Mexican subsidiary AlphaCare, sought FDA approval to import infant formulas into the US to help ease the national shortage. MyOr had 200,000 cans ready for shipment and capacity to produce an additional 250,000 monthly.

When did MyOr launch its NURTURE Precision Infant Care platform?

In June 2021, MYOR launched the NURTURE Precision Infant Care platform, an early intervention platform designed to identify high-allergy risk infants and provide guidelines for prevention and care. It was rolled out to clinics across the US.